SLC6A3 and Parkinson disease: The analyses in this report has 2 main aims: first, to describe the 5‐year change of the MDS‐UPDRS, other clinical outcome measures, and DAT binding; and second to assess the correlation between MDS‐UPDRS and DAT binding in this early PD cohort.